Revenues have continued to show good progress over the prior period, and results are expected to be in line with market expectations.
Further information will be provided in the full-year results announcement.
Revenues have continued to show good progress over the prior period, and results are expected to be in line with market expectations.
Further information will be provided in the full-year results announcement.
AstraZeneca Releases Enhertu Update
B.P. Marsh – Special Dividend Declaration
M.P. Evans Announces Acquisition
Henderson International Trust – Publication of Circular
GSK Releases Arexvy Update
GSK Releases Penmenvy Update
Delivered to your inbox every Friday